Bevacizumab Adoption Tied to Use by Peers
The decision to adopt bevacizumab could be appraised by the prior level of uptake among their peers in their medical community.
Gastrointestinal Cancers News
GASTROINTESTINAL CANCER ADVISOR
Gastrointestinal Cancers News
Ayvakit Approval for GI Stromal Tumor With PDGFRA Mutation
The FDA has approved Ayvakit (avapritinib; Blueprint Medicines Corporation), a tyrosine kinase inhibitor, for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
Higher Risk of GI Events During Immunotherapy for Patients With IBD
The study authors described the clinical benefit rate seen as similar to that reported in clinical trials.
Effects of Surgeon Volume, Nurse-to-Patient Ratio on Potential Complications With Pancreaticoduodenectomy
Although higher nurse-to-patient ratios ensure good outcomes for patients undergoing pancreaticoduodenectomy, PD-specific surgeon volume has a greater effect on risks of complications for these patients.
“Unexpected” CDH1 Variants Lead to Uncertainty, Experts Warn
Unexpectedly identifying a patient as a CDH1 carrier can lead to a “difficult conundrum” for clinicians and patients, highlighting the need for pretest counseling.
Updates to CRC Guidelines Increased Screening Uptake
After colorectal cancer screening guidelines lowered the age at which to start screening to age 45 years, increased screening rates followed among younger individuals.
Maintenance Therapy Lacks “Clear” OS Benefit in Metastatic CRC
Without a “clear” overall survival benefit from maintenance therapy, observation remains an option for patients with metastatic colorectal cancer.
Nivolumab Benefited MMR-Deficient Noncolorectal Cancers: NCI-MATCH
NCI-MATCH trial identified additional patients who may benefit from nivolumab.
CRC Screening Up for Ages 45 to 49 After ACS Guideline Update
Increase in screening rates in quarters 3, 4 of 2018 versus quarter 1; no change for people in their 50s
Gout May Be Associated With Protective Effect Against Colorectal Cancer
Researchers assessed the relationship between gout and colorectal cancer in a cohort of veterans.
Aspirin Use May Reduce Cancer, All-Cause Mortality in Seniors
Aspirin use three or more times per week tied to reduced all-cause, cancer, GI cancer, CRC mortality.
Ogivri, a Biosimilar to Herceptin, Now Available in the US
A biosimilar is a biological product that is approved based on data demonstrating high similarity to an FDA-approved biological product (reference product).
Testing for Genetic Variants Informed the Use of Cancer Risk Assessments
Genetic testing provided important information beyond personal and family history.
ASCO: Low-Dose Chemotherapy Benefits Advanced Gastroesophageal Cancer
Elderly, frail receiving 60 percent of oxaliplatin/capecitabine dose have noninferior PFS, less toxicity.
A Convolutional Neural Networks-Based Approach to the Analysis of Esophageal Biopsy Specimens
A convolutional neural networks-based approach to the analysis of images of histopathologic slides does not require prior slide annotation by a pathologist.
Gene Fusions Found in Pancreatic, Biliary IOPNs
Patterns of genetic alterations could guide management.
Long-Term Cancer Survivors Identify Ongoing Challenges Related to Ostomy Self-Management
In this study, researchers identified 8 common themes related to challenges patients experience with ostomy self-management.
Evidence Supports the Potential Use of KRAS(G12C) Inhibitor, Maybe Even in Combination
Preclinical and emerging clinical evidence support the possible use of AMG 510 as a single-agent KRAS (G12C) inhibitor, but preclinical evidence may also support the agent in combination.
MET Gene Amplification Found to Be Associated With Adverse Clinicopathological Features in Gallbladder Cancer
In this study, there was no correlation between the presence of MET gene amplification and the presence of MET protein overexpression.
Enhanced Recovery After Surgery Program Leads to Less Opioid Use After Colorectal Cancer Surgery
A retrospective chart review conducted after implementing an ERAS program demonstrated that improved patient education led to less use of opioids in the immediate postoperative period.
Want to read more?
Please login or register first to view this content.
Next post in Gastrointestinal Cancers News
